Expression Therapeutics Awarded NCI SBIR Grant to Advance ET501, a PTK7-Targeted γδ T-Cell Therapy for Children with High-Risk Neuroblastoma
National Cancer Institute (NCI) Small Business Innovation Research (SBIR) award funds development of ET501 toward an Investigational New Drug application ATLANTA, Oct. 15, 2026 /PRNewswire/ -- Expression Therapeutics, Inc., a clinical-stage gene and cell therapy company, today announced...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.